Lumida
/RGNX
⌘K
Regenxbio Inc

Regenxbio Inc

RGNX
$9.89USD↓-11.70%-1.31 today

MARKET CAP

511.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$8 – $10

52W RANGE

$5
$16

AI Summary

Stalk
StalkMedium

RGNX remains in a Stage 2 advance with clear higher highs and higher lows supported by rising short-term EMAs and expanding volume. The active Momentum Breakout signals new demand overwhelming prior supply at resistance. Price is extended above EMAs and in overbought territory, so short-term timing is unclear—execution should be deferred to pullbacks into rising EMA support or the breakout zone. Medium-term bias stays bullish while the long-term trend remains bearish.

  • ↑$100M AbbVie milestone from dosing first patient in Phase IIb/III trial.
  • ↑RGX202 hit primary endpoints in DMD trial with robust safety.
  • ↓Negative earnings yield and weak profitability hinder financial sustainability.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Regenexx Bio (NASDAQ: RGNX) is an emerging biotechnology company specializing in gene therapies aimed at treating rare diseases, particularly Duchenne muscular dystrophy (DMD) and diabetic retinopathy. With its innovative product pipeline—including RGX202 for DMD and ABBV-RGX-314 for diabetic retinopathy—the company is positioned to tackle significant unmet medical needs within the patient community. As Regenexx advances its clinical trials and regulatory pathways, it aims to establish itself as a leader in the gene therapy space amidst increasing competition.

Bull says

  • ↑$100M AbbVie milestone from dosing first patient in Phase IIb/III trial.
  • ↑RGX202 hit primary endpoints in DMD trial with robust safety.
  • ↑AbbVie partnership provides funding and expertise for diabetic retinopathy.
  • ↑$150M cash on hand plus upcoming milestones funds operations into 2027.
  • ↑Rapid enrollment of over 50 patients in RGX202 trial signals strong demand.
  • ↑High institutional ownership and positive earnings revisions reflect optimism.

Bear says

  • ↓Negative earnings yield and weak profitability hinder financial sustainability.
  • ↓High stock volatility may trigger steep price swings.
  • ↓FDA approval timelines risk delays due to regulatory complexities.
  • ↓Competition from Sarepta, Pfizer, and Bluebird could erode market share.
  • ↓R&D spend rose to $12M in Q1, up from $10M YoY, increasing cash burn.
  • ↓Low liquidity and high short interest amplify downside volatility.

Investment themes with RGNX

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-15-2026neutral

Transcript signals

Bull points

  • I'm thrilled to share that the pivotal phase three portion of the Affinity Duchenne trial of RGX202 met its primary endpoint with high statistical significance. Patients' functional outcomes exceeded expected disease trajectory across age groups and RGX202 was well tolerated.
  • The pivotal trial met the primary endpoint with high statistical significance, with 93% or 28 of 30 patients exceeding this threshold. Notably, 80% of patients exceeded 40% microdystrophin expression. We saw a 71.1% average microdystrophin expression across all patients and a 41.6% expression in patients aged eight and older.
  • We believe this robust expression supports the potential for improved outcomes. And as you'll see, this is supported by the strong correlation to function.

Bear points

  • we definitely need to concentrate in function. And what we're seeing on men needs two things. One, we're not treating patients early enough. And I think this is something that you guys are addressing, because we're gonna move into newborn screening. And if we're gonna end up in that area, we're gonna need therapies that are gonna address the situation as early as we can.
  • we definitely need to concentrate in function. And what we're seeing on men needs two things. One, we're not treating patients early enough. And I think this is something that you guys are addressing, because we're gonna move into newborn screening. And if we're gonna end up in that area, we're gonna need therapies that are gonna address the situation as early as we can.
  • Some of the families deal with the positivity of some of the AV vectors that might not make them candidates.
Read full transcript analysis ›